Tottenham accounts show Daniel Levy’s £3m stadium bonus

Tottenham, Daniel Levy, Stadium

Tottenham chairman Daniel Levy was paid a £3million bonus for delivering the club’s new stadium.

The hefty gift, which was additional to his £4million salary, was deferred from 2018 after Spurs moved into their 62,000-seater stadium – widely regarded as the best in the world – last April.

ALSO READ: COVID-19: Nigeria testing about 500 people per day ―NCDC DG

Levy was paid the bonus almost a year ago in 2019 and on Monday took a 20% pay cut along with all other non-playing staff as the club look to combat the coronavirus crisis.

The club accounts, published on Companies House website, read: “The total aggregate remuneration of directors, who are deemed to represent key management personnel, for the year ended 30 June 2019 was £6.4million.

ALSO READ: Coronavirus: UBA donates N28.5m to Anambra

“However, this amount excluded a bonus which was deferred from the year ended 30 June 2018 as it was contingent upon the completion of the stadium, which amounted to £3.9m, making the total aggregate remuneration for the year ended 30 June 2019 £10.3m.

“The highest-paid director received remuneration of £4m for the year in addition to the bonus deferred from the prior year of £3m, as explained above.”

Football 365

Vanguard

The post Tottenham accounts show Daniel Levy’s £3m stadium bonus appeared first on Vanguard News.

by Temisan Amoye via Vanguard News https://ift.tt/3bLcBk1 Best Known Member of the Cabinet Wikipedia

Comments

Effective Data Governance: IIM-Africa inks partnership deal with Data Management University

President/Chairman of the governing council of IIM-Africa, Dr. Oyedokun Oyewole has said that effective data governance strategy has become more essential for the survival and sustenance of government and businesses, especially with the sudden outbreak of COVID-19 Pandemic. Oyewole said there is the need to ensure that the right policies, processes, technology, and people are in place to effectively manage data while complying with legal and regulatory requirements. He said that as part of the IIM Africa’s commitments towards ensuring global best practices, it has entered into a long-term partnership with DataManagementU.com to bring the finest data management training to industries across Africa. READ ALSO: COVID-19: Foreign affairs minister says first set of Nigerians abroad to be evacuated soon According to the IIM President, the alliance is expected to provide members of the Institute and other professionals across Africa, high standards, internationally-recognized learn...

Naomi Osaka’s statement about withdrawing from French Open

Japan’s Naomi Osaka returns the ball to Romania’s Patricia Maria Tig during their first round match of the French open tennis tournament at the Roland Garros stadium Sunday, May 30, 2021 in Paris. (AP Photo/Christophe Ena) Naomi Osaka tweeted the following statement announcing her withdrawal from the French Open on Monday: “Hey everyone, this isn’t a situation I ever imagined or intended when I posted a few days ago. I think now the best thing for the tournament, the other players and my well-being is that I withdraw so that everyone can get back to focusing on the tennis going on in Paris. ”I never wanted to be a distraction and I accept that my timing was not idea and my message could have been clearer. ”More importantly I would never trivialize mental health or use the term lightly. The truth is that I have suffered long bouts of depression since the US Open in 2018 and I have had a really hard time coping with that. Anyone that knows me knows I’m introverted, and anyone tha...

Remdesivir: The COVID-19 drug helping patients recover faster

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. PHOTO: AP Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease. Here is what you need to know. – What is remdesivir? – Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever. It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines. That study concluded in 2019 when it was discontinued because it did not boost survival rates as greatly as two monoclonal antibody drugs, which are lab-engineered immune system proteins. In February, the US National Institute of Allergy and Infectious Diseases (NIAID) announced ...

Thorian

Search This Blog